Royalty Pharma (RPRX) Portfolio Receipts

Tracks the income generated from the company's portfolio of royalty interests, highlighting cash flow stability and the effectiveness of its investment strategy in acquiring lucrative royalty streams.

• Portfolio Receips
• Stock Price

Portfolio receipts accelerated into 2025 on big transactions, milestone timing and synthetic-royalty activity, producing record cash flow — but management’s 2026 guidance ( $3.275–3.425B) implies only mid-single-digit organic royalty growth absent new deals. In short, recent highs look partly transaction-driven, not a durable step-change; expect volatility from a planned drop in milestone cash, Promacta LOE and a U.S. Tysabri biosimilar, higher interest costs, and several concentrated clinical/arbitration outcomes that could swing receipts materially.